## Edgar Filing: ICU MEDICAL INC/DE - Form 4

ICU MEDICA	L INC/DE									
Form 4 April 03, 2017	7									
<u> </u>								OMB A	PPROVAL	
FORM	4 UNITED	STATES					E COMMISSION		3235-0287	
Check this if no longe: subject to Section 16. Form 4 or Form 5	Washington, D.C. 20549 F CHANGES IN BENEFICIAL OWNERSH SECURITIES					Expires: Estimated burden hou response	urs per			
obligations may contin <i>See</i> Instruc 1(b).	ue. Section 17(	a) of the H	Public U	Itility Hol	ding Cor		nge Act of 1934, c of 1935 or Sectio 1940	)n		
(Print or Type Re	esponses)									
1. Name and Ad RIGGS STEV	dress of Reporting /EN	Person <u>*</u>	Symbol	er Name <b>an</b> EDICAL		-	5. Relationship o Issuer	f Reporting Per	rson(s) to	
(Last)	(First) (1	Middle)					(Che	ck all applicabl	e)	
951 CALLE AMANECER			<ul><li>3. Date of Earliest Transaction (Month/Day/Year)</li><li>03/27/2017</li></ul>				Director 10% Owner X Officer (give title Other (specify below) below) VP Operations			
	(Street)			endment, D onth/Day/Yea	-	վ	6. Individual or J Applicable Line) _X_ Form filed by		erson	
SAN CLEME	ENTE, CA 9267	'3					Person		eporting	
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securities A	Acquired, Disposed of	of, or Beneficia	lly Owned	
	. Transaction Date Month/Day/Year)	Execution any	Date, if	3. Transactic Code (Instr. 8)	Disposed	(A) or of (D)	Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	or (D) Price	Transaction(s) (Instr. 3 and 4)			
Reminder: Repor	rt on a separate line	for each cla	ass of sec	urities bene	-	-	•			
					inforn requi	nation con red to resp ays a curre	spond to the colle- tained in this form ond unless the for ntly valid OMB co	are not m	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of	8.
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onof Derivative	Expiration Date	Underlying Securities	De
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	Se

## Edgar Filing: ICU MEDICAL INC/DE - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquire (A) or Dispose (D) (Instr. 3 and 5)	d of					(
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Common Stock (1)	\$ 0 <u>(2)</u>	03/27/2017 <u>(3)</u>		А		1,374		(4)	12/31/2019	Common Stock	1,374	
Common Stock (1)	\$ 0 <u>(2)</u>	03/27/2017 <u>(3)</u>		А		1,374		(5)	03/27/2020	Common Stock	1,374	

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships							
Reporting o when runne / runness	Director	10% Owner	Officer	Other				
RIGGS STEVEN 951 CALLE AMANECER SAN CLEMENTE, CA 92673			VP Operation	S				
Signatures								
By: Paula Darbyshire, Attorney-		04/03/2017						

Riggs

\*\*Signature of Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These securities are Restricted Stock Units.
- (2) There is neither a purchase price nor an exercise price for the Restricted Stock Units.
- (3) The executive officers were notified of their awards by the Registrant on March 30, 2017.

The vesting for this performance-based restricted stock unit ("PRSU") award is dependent upon the reporting person's earning PRSUs based on the achievement of performance criteria related to the Company's fiscal year 2019 Cumulative Adjusted EBITDA in comparison to the fiscal year 2016 A djusted EBITDA. The superbase of shares reported is the target super the superbased area and the start of the superbased and the superbased area area and the superbased area and the superbased area area and the superbased area area.

Date

- (4) based on the achievement of performance enterna related to the company's fiscal year 2019 cumulative Adjusted EBITDA in company of the target award amount. The reporting person may potentially earn PRSUs ranging from 100% to 300% of the target award amount.
- (5) One third of the Units subject to the award shall vest on each of the first, second, and third anniversaries of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(Iı